Modulation of autophagy as a therapeutic target in the treatment of metabolic dysfunction-associated steatotic liver disease: evidence from pharmacological, nutritional, and bioactive compound interventions
DOI:
https://doi.org/10.34119/bjhrv9n1-050Keywords:
metabolic dysfunction-associated steatotic liver disease, autophagy, liraglutide, metformin, bioactive compoundsAbstract
Metabolic dysfunction-associated steatotic liver disease is a global health problem driven primarily by obesity and insulin resistance. Growing evidence indicates that hepatic autophagy dysfunction contributes to lipid accumulation, inflammation, and disease progression, making this process a promising therapeutic target. This review discusses pharmacological, nutritional, and bioactive compound interventions that modulate autophagy. Among pharmacological therapies, in experimental models, liraglutide and metformin reportedly activate the AMP-activated protein kinase/ mammalian target of rapamycin pathway, increasing the expression of microtubule-associated proteins 1A/1B light chain 3 form II and beclin 1, decreasing sequestosome 1 expression, and augmenting the nuclear translocation of transcription factor EB, indicating effective autophagy induction. Moreover, nutritional strategies, such as calorie restriction and intermittent fasting, regulate energy-sensing pathways and have been associated with improvements in steatosis, oxidative stress, and metabolic parameters. Bioactive compounds also modulate autophagy signaling and reduce hepatic lipid accumulation. Taken together, the evidence reinforces autophagy as a central mechanism by which various therapeutic approaches can attenuate metabolic dysfunction-associated steatotic liver disease, supporting the development of more effective and mechanism-based interventions.
References
AGHABABAEI, F. et al. Recent Advances in Potential Health Benefits of Quercetin. Pharmaceuticals, [S.L.], v. 16, n. 7, p. 1020, 18 jul. 2023. https://doi.org/10.3390/ph16071020
BIFARI, F. et al. Multiple target tissue effects of GLP-1 analogues on non-alcoholic fatty liver disease (NAFLD) and non-alcoholic steatohepatitis (NASH). Pharmacological Research, [S.L.], v. 137, p. 219-229, nov. 2018. https://doi.org/10.1016/j.phrs.2018.09.025
BUGIANESI, E. et al. A Randomized Controlled Trial of Metformin versus Vitamin E or Prescriptive Diet in Nonalcoholic Fatty Liver Disease. The American Journal Of Gastroenterology, [S.L.], v. 100, n. 5, p. 1082-1090, maio 2005. https://doi.org/10.1111/j.1572-0241.2005.41583.x
CAPASSO, L. et al. Epigallocatechin Gallate (EGCG): pharmacological properties, biological activities and therapeutic potential. Molecules, [S.L.], v. 30, n. 3, p. 654, 1 fev. 2025. https://doi.org/10.3390/molecules30030654
CHAN, W. et al. Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD): a state-of-the-art review. Journal Of Obesity & Metabolic Syndrome, [S.L.], v. 32, n. 3, p. 197-213, 13 set. 2023. https://doi.org/10.7570/jomes23052
CHAUDHARY, R. et al. Intermittent fasting activates markers of autophagy in mouse liver, but not muscle from mouse or humans. Nutrition, [S.L.], v. 101, p. 111662, set. 2022. https://doi.org/10.1016/j.nut.2022.111662
CHEN, L. et al. Quercetin and non-alcoholic fatty liver disease: a review based on experimental data and bioinformatic analysis. Food And Chemical Toxicology, [S.L.], v. 154, p. 112314, ago. 2021. https://doi.org/10.1016/j.fct.2021.112314
CHOI, C. et al. Epigallocatechin-3-Gallate Reduces Visceral Adiposity Partly through the Regulation of Beclin1-Dependent Autophagy in White Adipose Tissues. Nutrients, [S.L.], v. 12, n. 10, p. 3072, 8 out. 2020. https://doi.org/10.3390/nu12103072
COLMAN, R. et al. Caloric Restriction Delays Disease Onset and Mortality in Rhesus Monkeys. Science, [S.L.], v. 325, n. 5937, p. 201-204, 10 jul. 2009. https://doi.org/10.1126/science.1173635
COLMAN, R. et al. Caloric restriction reduces age-related and all-cause mortality in rhesus monkeys. Nature Communications, [S.L.], v. 5, n. 1, p. 1-5, 1 abr. 2014. https://doi.org/10.1038/ncomms4557
DANN, S. et al. MTOR Complex1–S6K1 signaling: at the crossroads of obesity, diabetes and cancer. Trends In Molecular Medicine, [S.L.], v. 13, n. 6, p. 252-259, jun. 2007. https://doi.org/10.1016/j.molmed.2007.04.002
DING, S. et al. Resveratrol and caloric restriction prevent hepatic steatosis by regulating SIRT1-autophagy pathway and alleviating endoplasmic reticulum stress in high-fat diet-fed rats. Plos One, [S.L.], v. 12, n. 8, p. 0183541, 17 ago. 2017. https://doi.org/10.1371/journal.pone.0183541
ESLAM, M. et al. MAFLD: a consensus-driven proposed nomenclature for metabolic associated fatty liver disease. Gastroenterology, [S.L.], v. 158, n. 7, p. 1999-2014.1, maio 2020. https://doi.org/10.1053/j.gastro.2019.11.312
FANG, Y. et al. Liraglutide Alleviates Hepatic Steatosis by Activating the TFEB-Regulated Autophagy-Lysosomal Pathway. Frontiers In Cell And Developmental Biology, [S.L.], v. 8, p. 1-15, 27 nov. 2020. https://doi.org/10.3389/fcell.2020.602574
FUJIMORI, M. et al. Enhanced solubility of quercetin by forming composite particles with transglycosylated materials. Journal Of Food Engineering, [S.L.], v. 149, p. 248-254, mar. 2015. https://doi.org/10.1016/j.jfoodeng.2014.10.010
GAO, C. et al. Metformin Induces Autophagy via the AMPK-mTOR Signaling Pathway in Human Hepatocellular Carcinoma Cells. Cancer Management And Research, [S.L.], v. 12, p. 5803-5811, jul. 2020. https://doi.org/10.2147/CMAR.S257966
GHOSAL, S. et al. A meta-analysis of the effects of glucagon-like-peptide 1 receptor agonist (GLP1-RA) in nonalcoholic fatty liver disease (NAFLD) with type 2 diabetes (T2D). Scientific Reports, [S.L.], v. 11, n. 1, p. 1-8, 11 nov. 2021. https://doi.org/10.1038/s41598-021-01663-y
GLUCHOWSKI, N. et al. Lipid droplets and liver disease: from basic biology to clinical implications. Nature Reviews Gastroenterology & Hepatology, [S.L.], v. 14, n. 6, p. 343-355, 21 abr. 2017. https://doi.org/10.1038/nrgastro.2017.32
GUO, Z. et al. Mechanism of action of quercetin in regulating cellular autophagy in multiple organs of Goto-Kakizaki rats through the PI3K/Akt/mTOR pathway. Frontiers In Medicine, [S.L.], v. 11, p. 1-15, 15 ago. 2024. https://doi.org/10.3389/fmed.2024.1442071
HE, Q. et al. GLP-1 analogue improves hepatic lipid accumulation by inducing autophagy via AMPK/mTOR pathway. Biochemical And Biophysical Research Communications, [S.L.], v. 476, n. 4, p. 196-203, ago. 2016. https://doi.org/10.1016/j.bbrc.2016.05.086
HE, Y. et al. The preventive effect of liraglutide on the lipotoxic liver injury via increasing autophagy. Annals Of Hepatology, [S.L.], v. 19, n. 1, p. 44-52, jan. 2020. https://doi.org/10.1016/j.aohep.2019.06.023
HEFER, M. et al. Green Tea Polyphenol (-)-Epicatechin Pretreatment Mitigates Hepatic Steatosis in an In Vitro MASLD Model. Current Issues In Molecular Biology, [S.L.], v. 46, n. 8, p. 8981-8994, 16 ago. 2024. https://doi.org/10.3390/cimb46080531
HIDALGO, I. et al. Is it possible to treat nonalcoholic liver disease using a flavanol-based nutraceutical approach? Basic and clinical data. Journal Of Basic And Clinical Physiology And Pharmacology, [S.L.], v. 33, n. 6, p. 703-714, 4 fev. 2022. https://doi.org/10.1515/jbcpp-2021-0285
ISAACS, S. et al. Role of anti-diabetic medications in the management of MASLD. Frontline Gastroenterology, [S.L.], v. 16, n. 3, p. 239-249, 19 fev. 2025. BMJ. http://dx.doi.org/10.1136/flgastro-2024-102856. https://doi.org/10.1136/flgastro-2024-102856
JAFARI, M. et al. Calorie restriction and calorie-restriction mimetics activate chaperone-mediated autophagy. Proceedings Of The National Academy Of Sciences, [S.L.], v. 121, n. 26, p. 1-12, 18 jun. 2024. https://doi.org/10.1073/pnas.2317945121
JAKUBEK, P. et al. Autophagy alterations in obesity, type 2 diabetes, and metabolic dysfunction-associated steatotic liver disease: the evidence from human studies. Internal And Emergency Medicine, [S.L.], v. 19, n. 5, p. 1473-1491, 6 jul. 2024. https://doi.org/10.1007/s11739-024-03700-w
JANOTA, B. et al. Dietary Strategies in the Prevention of MASLD: a comprehensive review of dietary patterns against fatty liver. Metabolites, [S.L.], v. 15, n. 8, p. 528, 4 ago. 2025. https://doi.org/10.3390/metabo15080528
JIN, T.; WENG, J. Hepatic functions of GLP-1 and its based drugs: current disputes and perspectives. American Journal of Physiology – Endocrinology and Metabolism, v. 311, n. 3, p. E620–E627, 2016.https://doi.org/10.1152/ajpendo.00069.201
JOHARI, M. et al. A Randomised Controlled Trial on the Effectiveness and Adherence of Modified Alternate-day Calorie Restriction in Improving Activity of Non-Alcoholic Fatty Liver Disease. Scientific Reports, [S.L.], v. 9, n. 1, p. 1-9, 2 ago. 2019. https://doi.org/10.1038/s41598-019-47763-8
KARAHAN, T. et al. Effects of Intermittent Fasting on Liver Steatosis and Fibrosis, Serum FGF-21 and Autophagy Markers in Metabolic Dysfunction-Associated Fatty Liver Disease: a randomized controlled trial. Life, [S.L.], v. 15, n. 5, p. 696, 25 abr. 2025. https://doi.org/10.3390/life15050696
KATSAROS, I. et al. Quercetin’s Potential in MASLD: investigating the role of autophagy and key molecular pathways in liver steatosis and inflammation. Nutrients, [S.L.], v. 16, n. 22, p. 3789, 5 nov. 2024. https://doi.org/10.3390/nu16223789
KATSAROS, I. et al. The Effect of Quercetin on Non-Alcoholic Fatty Liver Disease (NAFLD) and the Role of Beclin1, P62, and LC3: an experimental study. Nutrients, [S.L.], v. 16, n. 24, p. 4282, 11 dez. 2024. https://doi.org/10.3390/nu16244282
KIM, S. et al. Effects of Epigallocatechin-3-Gallate on Autophagic Lipolysis in Adipocytes. Nutrients, [S.L.], v. 9, n. 7, p. 680, 30 jun. 2017. https://doi.org/10.3390/nu9070680
KOUTOUKIDIS, D. et al. Association of Weight Loss Interventions With Changes in Biomarkers of Nonalcoholic Fatty Liver Disease. Jama Internal Medicine, [S.L.], v. 179, n. 9, p. 1262, 1 set. 2019. https://doi.org/10.1001/jamainternmed.2019.2248
LI, Z. et al. Liraglutide protects against inflammatory stress in non-alcoholic fatty liver by modulating Kupffer cells M2 polarization via cAMP-PKA-STAT3 signaling pathway. Biochemical And Biophysical Research Communications, [S.L.], v. 510, n. 1, p. 20-26, fev. 2019. https://doi.org/10.1016/j.bbrc.2018.12.149
LIAO, Z. et al. Liraglutide Improves Nonalcoholic Fatty Liver Disease in Diabetic Mice by Activating Autophagy Through AMPK/mTOR Signaling Pathway. Diabetes, Metabolic Syndrome And Obesity, [S.L.], v. 17, p. 575-584, fev. 2024.https://doi.org/10.2147/DMSO.S447182
LIU, L. et al. Quercetin Alleviates High-Fat Diet-Induced Oxidized Low-Density Lipoprotein Accumulation in the Liver: implication for autophagy regulation. Biomed Research International, [S.L.], v. 2015, p. 1-9, 2015. https://doi.org/10.1155/2015/607531
LIU, P. et al. Frataxin‐Mediated PINK1–Parkin‐Dependent Mitophagy in Hepatic Steatosis: the protective effects of quercetin. Molecular Nutrition & Food Research, [S.L.], v. 62, n. 16, p. 1-40, 26 jul. 2018. https://doi.org/10.1002/mnfr.201800164
LOOMBA, R. et al. Clinical trial: pilot study of metformin for the treatment of non⠰alcoholic steatohepatitis. Alimentary Pharmacology & Therapeutics, [S.L.], v. 29, n. 2, p. 172-182, 16 dez. 2008. https://doi.org/10.1111/j.1365-2036.2008.03869.x
LUO, Y. et al. Liraglutide Improves Non-Alcoholic Fatty Liver Disease In Diabetic Mice By Modulating Inflammatory Signaling Pathways. Drug Design, Development And Therapy, [S.L.], v. 13, p. 4065-4074, dez. 2019. https://doi.org/10.2147/DDDT.S224688
MIAO, L. et al. Current status and future trends of the global burden of MASLD. Trends In Endocrinology & Metabolism, [S.L.], v. 35, n. 8, p. 697-707, ago. 2024. https://doi.org/10.1016/j.tem.2024.02.007
MILTONPRABU, S. et al. Hepatoprotective effect of quercetin: from chemistry to medicine. Food And Chemical Toxicology, [S.L.], v. 108, p. 365-374, out. 2017. https://doi.org/10.1016/j.fct.2016.08.034
MOREIRA, R. et al. Brazilian evidence-based guideline for screening, diagnosis, treatment, and follow-up of metabolic dysfunction-associated steatotic liver disease (MASLD) in adult individuals with overweight or obesity: a joint position statement from the brazilian society of endocrinology and metabolism (sbem), brazilian society of hepatology (sbh), and brazilian association for the study of obesity and metabolic syndrome (abeso). Archives Of Endocrinology And Metabolism, [S.L.], v. 67, n. 6, p. 1-23, 2023. https://doi.org/10.20945/2359-4292-2023-0123
MOST, J. et al. Calorie restriction in humans: an update. Ageing Research Reviews, [S.L.], v. 39, p. 36-45, out. 2017. https://doi.org/10.1016/j.arr.2016.08.005
NEWSOME, P. et al. A Placebo-Controlled Trial of Subcutaneous Semaglutide in Nonalcoholic Steatohepatitis. New England Journal Of Medicine, [S.L.], v. 384, n. 12, p. 1113-1124, 25 mar. 2021. https://doi.org/10.1056/NEJMoa2028395
REZAEI, S. et al. GLP‐1 Receptor Agonist Effects on Lipid and Liver Profiles in Patients with Nonalcoholic Fatty Liver Disease: systematic review and meta⠰analysis. Canadian Journal Of Gastroenterology And Hepatology, [S.L.], v. 2021, n. 1, p. 1-11, jan. 2021. https://doi.org/10.1155/2021/8936865
SANGRO, P. et al. Metabolic dysfunction–associated fatty liver disease (MAFLD): an update of the recent advances in pharmacological treatment. Journal Of Physiology And Biochemistry, [S.L.], v. 79, n. 4, p. 869-879, 28 mar. 2023. https://doi.org/10.1007/s13105-023-00954-4
SANTAMARINA, A. et al. Green Tea Extract Rich in Epigallocatechin-3-Gallate Prevents Fatty Liver by AMPK Activation via LKB1 in Mice Fed a High-Fat Diet. Plos One, [S.L.], v. 10, n. 11, p. 0141227, 4 nov. 2015. https://doi.org/10.1371/journal.pone.0141227
SAXTON, R. et al. MTOR Signaling in Growth, Metabolism, and Disease. Cell, [S.L.], v. 168, n. 6, p. 960-976, mar. 2017.https://doi.org/10.1016/j.cell.2017.02.004
SIMANCAS-RACINES, D. et al. Nutritional Strategies for Battling Obesity-Linked Liver Disease: the role of medical nutritional therapy in metabolic dysfunction-associated steatotic liver disease (masld) management. Current Obesity Reports, [S.L.], v. 14, n. 1, p. 1-16, 11 jan. 2025. https://doi.org/10.1007/s13679-024-00597-6
SOTIROPOULOU, M. et al. Nonalcoholic fatty liver disease. Saudi Journal Of Gastroenterology, [S.L.], v. 27, n. 6, p. 319-330, nov. 2021. https://doi.org/10.4103/sjg.sjg_249_21
TONG, W. et al. Liraglutide ameliorates non‐alcoholic fatty liver disease by enhancing mitochondrial architecture and promoting autophagy through the SIRT1/SIRT3–FOXO3a pathway. Hepatology Research, [S.L.], v. 46, n. 9, p. 933-943, 11 jan. 2016. https://doi.org/10.1111/hepr.12634
UM, S. et al. Absence of S6K1 protects against age- and diet-induced obesity while enhancing insulin sensitivity. Nature, [S.L.], v. 431, n. 7005, p. 200-205, 11 ago. 2004. https://doi.org/10.1038/nature02866
VASIM, I. et al. Intermittent Fasting and Metabolic Health. Nutrients, [S.L.], v. 14, n. 3, p. 631, 31 jan. 2022. https://doi.org/10.3390/nu14030631
WANG, W. et al. The biological activities, chemical stability, metabolism and delivery systems of quercetin: a review. Trends In Food Science & Technology, [S.L.], v. 56, p. 21-38, out. 2016. https://doi.org/10.1016/j.tifs.2016.07.004
WILKINSON, M. et al. Ten-Hour Time-Restricted Eating Reduces Weight, Blood Pressure, and Atherogenic Lipids in Patients with Metabolic Syndrome. Cell Metabolism, [S.L.], v. 31, n. 1, p. 92-104.5, jan. 2020. https://doi.org/10.1016/j.cmet.2019.11.004
XIANG, H. et al. Targeting autophagy-related protein kinases for potential therapeutic purpose. Acta Pharmaceutica Sinica B, [S.L.], v. 10, n. 4, p. 569-581, abr. 2020. https://doi.org/10.1016/j.apsb.2019.10.003
XIAO, Y et al. Effect of 5:2 fasting diet on liver fat content in patients with type 2 diabetic with nonalcoholic fatty liver disease. Metabolic Syndrome and Related Disorders, v. 20, n. 8, p. 459–465, 2022. https://doi.org/10.1089/met.2022.001
YANAI, H. et al. Metabolic-Dysfunction-Associated Steatotic Liver Disease—Its Pathophysiology, Association with Atherosclerosis and Cardiovascular Disease, and Treatments. International Journal Of Molecular Sciences, [S.L.], v. 24, n. 20, p. 15473, 23 out. 2023. https://doi.org/10.3390/ijms242015473
ZECHNER, R. et al. Cytosolic lipolysis and lipophagy: two sides of the same coin. Nature Reviews Molecular Cell Biology, [S.L.], v. 18, n. 11, p. 671-684, 30 ago. 2017. https://doi.org/10.1038/nrm.2017.76
ZHANG, D. et al. Metformin Alleviates Hepatic Steatosis and Insulin Resistance in a Mouse Model of High-Fat Diet-Induced Nonalcoholic Fatty Liver Disease by Promoting Transcription Factor EB-Dependent Autophagy. Frontiers In Pharmacology, [S.L.], v. 12, p. 1-10, 23 jul. 2021. https://doi.org/10.3389/fphar.2021.689111
ZHANG, J. et al. Green tea epigallocatechin gallate attenuate metabolic dysfunction-associated steatotic liver disease by regulation of pyroptosis. Lipids In Health And Disease, [S.L.], v. 24, n. 1, p. 1-13, 17 maio 2025. https://doi.org/10.1186/s12944-025-02596-5
ZHANG, Z. et al. Intermittent fasting and metabolic dysfunction-associated steatotic liver disease: the potential role of the gut-liver axis. Cell & Bioscience, [S.L.], v. 15, n. 1, p. 1-27, 23 maio 2025. https://doi.org/10.1186/s13578-025-01406-w
ZHOU, J. et al. Epigallocatechin-3-Gallate (EGCG), a Green Tea Polyphenol, Stimulates Hepatic Autophagy and Lipid Clearance. Plos One, [S.L.], v. 9, n. 1, p. 87161, 29 jan. 2014. https://doi.org/10.1371/journal.pone.0087161
